Clinical effects of ezetimibe on improving lipid metabolism and prognostic impact in patients after percutaneous coronary intervention surgery

AIM To observe the effect of ezetimibe combined with atorvastatin on blood lipid metabolism and prognostic impact in patients after percutaneous coronary intervention (PCI) surgery. METHODS 180 patients were randomly divided into a combined treatment group and an atorvastatin group. Changes were measured in serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and serum high sensitive C reactive protein (hs-CRP) and compared between the two groups in six months after treatment. The changes were compared with the incidence of major adverse cardiac cerebral vascular events (MACCE) beween the two groups. RESULTS The serum levels of TC, LDL-C and hs-CRP were significantly lower than those before the treatment in both of the two groups, combined treatment group serum TC(3.0±0.8) mmol/L vs.(4.2±0.9) mmol/L, P<0.05, LDL-C(2.0±0.8) mmol/L vs.(2.4±1.0) mmol/L, and hs-CRP(2.6±5.0) mg/L vs.(3.7±4.5) mg/L, P<0.05 decreased significantly compared with atorvastatin group; the incidence of MACCE was significantly lower in combined treatment group than atorvastatin group (7% vs. 18%, P<0.05). CONCLUSION Ezetimibe combined with atorvastatin effectively improve serum TC, LDL-C and hs-CRP levels in patients after PCI surgery, and also reduce the incidence of MACCE, which has better clinical application value.